WAT

Business Profile & Competitive Position

Waters Corporation operates in the Healthcare sector, specifically in the Medical – Diagnostics & Research industry. The company designs, manufactures, sells, and services analytical technologies used in laboratories worldwide. Its core technologies include high-performance and ultra-performance liquid chromatography (LC), mass spectrometry (MS), and thermal analysis, rheometry, and calorimetry (TA) instruments. These are typically sold as integrated LC-MS systems running common software, supported by consumables, software, and service contracts. Customers span pharmaceutical, clinical, biochemical, industrial, nutritional safety, environmental, academic, and government laboratories.

After the February 9, 2026 acquisition of BD's Biosciences and Diagnostic Solutions businesses, Waters' portfolio also includes diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry, and multiomics tools. In 2025, 59% of net sales went to pharmaceutical accounts, 30% to other industrial accounts, and 11% to academic and government agencies. No single customer represented more than 2% of net sales, which points to a diversified customer base rather than heavy reliance on any one buyer.

Competitive moat, however, is harder to infer from current profitability metrics. The company’s net margin is 3.6% and its return on equity (ROE) is 1.9%. Those figures are modest for a specialized analytical-instrument business and suggest that, at least for now, Waters is not converting sales into high bottom-line profitability or generating strong returns on shareholder capital. Service revenue represented more than 35% of 2025 sales and more than 25% of TA’s 2025 sales, which is a stabilizing, recurring element, but the low margin and ROE imply that pricing power and capital efficiency are currently under pressure—likely reflecting deal costs, integration expenses, and elevated R&D spending tied to the BD acquisition.

Financial Posture

Waters carries a market capitalization of $30.6 billion and trades at a price-to-earnings ratio of 101.8. That is a very high multiple by most Healthcare standards and implies the market is pricing in a meaningful rebound in earnings once the BD integration matures. The current net margin of 3.6% and ROE of 1.9%, however, do not on their own justify such a valuation multiple unless profitability recovers meaningfully. The stock’s beta is 1.19, meaning it has historically moved slightly more than the broader market.

The $16.8 billion acquisition of BD’s Biosciences and Diagnostic Solutions businesses—including assumed debt—transformed Waters’ scale and balance sheet. BD shareholders own approximately 39.2% of the combined company, so a large block of equity now sits with former BD owners. This transaction added a diagnostics business with different margin, regulatory, and capital profiles than Waters’ legacy analytical-instrument franchise, so today’s blended valuation multiples reflect both businesses as well as the cost and revenue synergies that management expects to capture.

Strategic Priorities & Outlook

According to Waters’ most recent SEC 10-K filing, the company is reorganizing the combined entity into four segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. Management says it is evaluating these newly organized business activities to determine operating and reporting segments for future reporting periods, which could change how investors analyze segment profitability and growth.

The filing also emphasizes continued significant research and development investment to develop new products and enhance existing LC, MS, TA, and diagnostics offerings. The company plans to pursue additional outsourcing opportunities as they arise, while maintaining adequate internal supply chain and manufacturing capabilities. In practical terms, the outlook for the next several quarters is dominated by executing the BD integration, defining the segment structure, and bringing new products to market while keeping operations running.

Macro & Geopolitical Exposure

As a Diagnostics & Research business under the Healthcare umbrella, Waters is exposed to several macro and policy channels. Regulatory scrutiny is one: LC, MS, and diagnostics products are subject to FDA, EMA, and other global health-agency requirements, and any change in device or diagnostic approval timelines can affect product launches and revenue recognition. Reimbursement policy also matters for diagnostics, particularly for the newly acquired cancer and infectious-disease testing business where test adoption partly depends on payer coverage.

Pharmaceutical R&D spending is another driver, since 59% of 2025 sales went to pharma accounts. If large drug companies cut capital budgets or delay instrument purchases, Waters would likely feel the impact. Academic and government labs accounted for 11% of sales, so public research funding and grant budgets influence demand. Trade policy, tariffs, and supply-chain disruptions can affect the sourcing of components and the cost of manufacturing analytical instruments, while currency fluctuations impact reported results because sales are global.

Recent Developments

Recent news has carried a generally constructive tone. On September 3, 2026, Zacks published “Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?,” noting post-report strength. On September 2, 2026, Defenseworld.net reported that Benjamin Edwards Inc. had purchased shares of Waters Corporation. On August 27, 2026, Benzinga highlighted a bullish turn by one Waters analyst as part of its “Top 3 Upgrades For Thursday” list. Also on August 27, 2026, Business Wire announced that LetsGetChecked, powered by Fuze Health, had partnered with Waters to bring what they described as the most comprehensive FDA-cleared at-home HPV cervical cancer screening tool available in the U.S. to patients. That partnership fits with Waters’ expanded diagnostics footprint following the BD acquisition.

Earnings Behavior & Post-Earnings Drift

Waters has established a strong earnings track record over the past eight quarters: it beat consensus earnings estimates in all eight quarters, for a 100% beat rate, with an average earnings surprise of 4.7%. In the five trading days following each report, the stock posted an average gain of 2.67%, classified as an upward post-earnings drift.

The most recent reported quarter, August 4, 2026, delivered actual EPS of $3.05 against an estimate of $3.01, a 1.3% surprise. The stock rose 0.99% the next day and 4.78% over the following five sessions. Before that, the May 5, 2026 quarter produced EPS of $2.70 versus $2.31 estimated, a 16.9% surprise, with a next-day gain of 2.04% and a five-day gain of 2.83%. The February 9, 2026 quarter delivered $4.53 versus $4.51 (0.4% surprise), but the stock fell 0.34% the next day and 2.04% over the next five days. The November 4, 2025 quarter saw EPS of $3.40 versus $3.21 estimated (5.9% surprise), with a next-day gain of 1.26% and a five-day gain of 5.12%.

The next scheduled report is November 3, 2026, before the market opens, with a consensus EPS estimate of $4.01. Because Waters has beaten expectations in every one of the last eight quarters, the market's real expectation may be more demanding than the published consensus, and any disappointment could be magnified despite the historical beat streak.

For a deeper dive, consider reviewing the full institutional verdict, which can add context from analyst models, rating changes, and forward estimates beyond the figures covered here.